Algert Global LLC Takes $1.81 Million Position in Evolent Health, Inc $EVH

Key Points

• Algert Global LLC has acquired a new position in Evolent Health, purchasing 191,581 shares valued at approximately $1,814,000, according to their recent SEC filing.
• Several institutional investors have increased their holdings in Evolent Health, with Cadian Capital Management leading with a new position valued at $58,781,000.
• Despite Evolent Health's disappointing earnings report, analysts maintain a generally positive outlook, with an average price target of $17.93 and multiple "buy" ratings from research firms.

Algert Global LLC acquired a new stake in Evolent Health, Inc (NYSE:EVH - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 191,581 shares of the technology company's stock, valued at approximately $1,814,000. Algert Global LLC owned approximately 0.16% of Evolent Health as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Engaged Capital LLC raised its holdings in shares of Evolent Health by 35.5% during the 4th quarter. Engaged Capital LLC now owns 5,404,768 shares of the technology company's stock worth $60,804,000 after acquiring an additional 1,415,300 shares during the period. Cadian Capital Management LP purchased a new position in shares of Evolent Health during the 4th quarter worth $58,781,000. Granahan Investment Management LLC raised its holdings in shares of Evolent Health by 5.2% during the 4th quarter. Granahan Investment Management LLC now owns 3,673,710 shares of the technology company's stock worth $41,329,000 after acquiring an additional 181,893 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Evolent Health by 19.2% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,897,443 shares of the technology company's stock worth $32,595,000 after acquiring an additional 466,225 shares during the period. Finally, Silvercrest Asset Management Group LLC raised its holdings in shares of Evolent Health by 37.3% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 1,371,053 shares of the technology company's stock worth $15,424,000 after acquiring an additional 372,793 shares during the period.

Analyst Ratings Changes

Several research firms have recently commented on EVH. Truist Financial lifted their price target on Evolent Health from $14.00 to $16.00 and gave the stock a "buy" rating in a report on Thursday, July 17th. UBS Group raised their price objective on Evolent Health from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Friday, May 9th. Needham & Company LLC restated a "buy" rating and issued a $15.00 price objective on shares of Evolent Health in a report on Tuesday, May 13th. Finally, JMP Securities restated a "market outperform" rating and issued a $13.00 price objective on shares of Evolent Health in a report on Friday, June 20th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, Evolent Health presently has an average rating of "Buy" and a consensus price target of $17.93.

Evolent Health Trading Up 4.0%

NYSE EVH traded up $0.38 during trading on Wednesday, hitting $9.65. The stock had a trading volume of 6,651,468 shares, compared to its average volume of 3,560,548. The company has a market capitalization of $1.13 billion, a PE ratio of -5.99 and a beta of 0.82. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.72. The firm has a 50 day moving average price of $10.13 and a 200 day moving average price of $9.55. Evolent Health, Inc has a twelve month low of $7.06 and a twelve month high of $32.35.

Evolent Health (NYSE:EVH - Get Free Report) last released its earnings results on Thursday, August 7th. The technology company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.20). The firm had revenue of $444.33 million during the quarter, compared to analyst estimates of $459.43 million. Evolent Health had a negative net margin of 5.94% and a positive return on equity of 1.83%. The business's revenue was down 31.3% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.30 earnings per share. Evolent Health has set its Q3 2025 guidance at EPS. As a group, equities research analysts forecast that Evolent Health, Inc will post 0.08 earnings per share for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.